Are the impairments of arginine metabolism as found in Alzheimer's disease also present in patients developing post-operative delirium and cognitive decline?
Are the impairments of arginine metabolism as found in Alzheimer's disease also present in patients developing post-operative delirium and cognitive decline?
批准号:
10810134
负责人:
Emma Louise Cunningham
金额:
$20.08万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-15 至 2026-05-31
中文摘要
摘要:老年人在做手术时需要特别护理,主要是因为周围发生了一些事情
手术和麻醉会导致神志不清。术后精神错乱的发生率取决于
手术,但总体术后发病率为17%是一个合理的估计。病理生理学
术后精神错乱及其后遗症的发病机制尚未得到系统的研究。一定的
途径可能解释了精神错乱本身的发展,而其他途径可能驱动更长时间的认知。
结果,如痴呆症的进展。它们相互关联、分离或共享的程度是
完全未知。研究精神错乱的神经基础的一种方法是使用脑脊液样本。
通过区域麻醉获得。我们建议用脑脊液研究妄想的神经基础。
腰麻过程中获得的样本,结合临床和人口学的生物标记物
信息。我们的初步数据表明,精氨酸代谢可能是脑脊液中精神错乱的预测因子。在这
我们的研究目标是在以前工作的基础上,准确地定量所有与精氨酸相关的代谢物和
用这个代谢级联的蛋白质表达水平来补充这个数据集。我们的目标是开发一种
脑脊液中精氨酸代谢的全面图像,并将这些结果与当前的病理生理相关联
阿尔茨海默病的生物标志物。此外,在扩大了精氨酸代谢的生物化学覆盖范围后,
我们将开发新的生物标志物,能够预测那些最有可能发展为精神错乱和精神错乱的患者
随之而来的认知衰退。定义了精神错乱的生化特征后,重要的是
确定哪些患者后来患上了痴呆症和/或手术后严重的神经变性。
因此,我们将完成对原始患者的长期随访,以确定谁患上了阿尔茨海默氏症
并将这些发现与我们的结果相关联。此外,为了确保
我们的精神错乱生物标志物小组的有效性,我们将前瞻性地招募接受计划的联合
博蒙特健康公司的替代手术(博蒙特皇家橡树公司的4,000台,2018年),进行术前临床
以及认知评估和术后精神错乱筛查。有机会接触到如此庞大和多样化的
患者群体将为我们提供一个最佳的、独立的验证集。总而言之,我们最重要的是
这项提议的目标是:(I)与最大的脑脊液-神志不清储存库发展现有的合作关系,以
日期(n=358),以扩展目前的发现;(Ii)开发新的生物标志物小组;(Iii)执行长期
对我们最初的队列进行跟踪,并(Iv)在美国的一个庞大而多样化的人群中验证我们的发现。
英文摘要
Abstract: Older people require specific care when undergoing an operation, principally because events around
surgery and anesthesia can precipitate delirium. The prevalence of postoperative delirium depends on type of
surgery, but an overall postoperative incidence of 17% is a reasonable estimate. The pathophysiological
mechanisms that underpin postoperative delirium and its sequelae have yet to be systematically studied. Certain
pathways may account for the development of delirium itself, while others may drive longer-term cognitive
outcomes such as progression of dementia. The degree to which these interrelate, are separate or shared is
completely unknown. One approach to investigate the neural basis of delirium has been to use CSF samples
obtained through regional anesthesia. We propose investigating the neural basis of delirium by using CSF
samples obtained in the course of spinal anesthesia, combining biomarkers with clinical and demographic
information. Our preliminary data indicates arginine metabolism may be a predictor of delirium in CSF. In this
study we aim to extend on our previous work, and accurately quantify all arginine related metabolites and
complement this data set with protein expression levels for this metabolic cascade. Our goal is to develop a
comprehensive picture of arginine metabolism in CSF and correlate these results with current pathophysiological
biomarkers of Alzheimer’s disease. Further, having extended our biochemical coverage of arginine metabolism,
we will develop novel biomarkers capable of predicting those patients at greatest risk of developing delirium and
subsequent cognitive decline. Having defined the biochemical signature of delirium, it will be important to
determine which patients later developed dementia and/or significant neurodegeneration following surgery.
Therefore, we will complete a long term follow up of our original patients to determine who developed Alzheimer’s
disease or one of its related dementias and correlate those findings with our results. Moreover, and to ensure
the validity of our delirium biomarker panel, we will prospectively recruit participants undergoing planned joint
replacement surgery at Beaumont Health (>4,000 at Beaumont Royal Oak, 2018), perform pre-operative clinical
and cognitive assessments and postoperative delirium screening. Having access to such a large and diverse
patient population will provide the us with an optimal, independent validation set. In summary, our overarching
goals for this proposal are to: (i) develop an existing collaboration with the largest CSF-delirium repository to
date (n=358) in order to extend on current findings; (ii) develop new biomarker panels; (iii) perform a long term
follow up of our initial cohort and (iv) validate our findings in a large and diverse US based population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
IL-4协同精氨酸优化种植初期巨噬细胞胞葬作用和成骨微环境的作用及机制研究
-
批准号:82370923
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张文杰
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
糖尿病性勃起功能障碍阴茎海绵体线粒体氧化应激损伤与保护机制研究
-
批准号:30801143
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2008
-
负责人:陈赟
-
依托单位: